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Introduction
Diseases caused by Streptococcus pneumoniae are re-
sponsible of high morbidity and mortality all over Eu-
rope [1]. In addition, the problem of multidrug resistance 
(MDR) has recently emerged, due to the great and often 
unnecessary usage of antibiotics for the treatment of acute 
otitis media (AOM) in children [2, 3]. For these reasons, 
the prevention of infections related to S. pneumoniae has 
become a priority in the Public Health field. 
As for the rising and growing problem of MDR, the new 
vaccines which prevent diseases caused by the higher 
resistant and newly emerging serotypes seem to be an 
important tool for lowering the burden of disease due to 
S. pneumoniae [4-7]. 
Nowadays, there are two big classes of vaccines which 
protect from pneumococcal diseases [8]: 
•	 the	conjugate	vaccines	(PCVs),	obtained	by	the	con-
jugation of a carrier protein to the capsular polysac-
charide; 
•	 the	polysaccharide	vaccines	 (PPVs),	 containing	 the	
purified capsular polysaccharide. 
The PCVs bring to the production of high antibody levels 
in children, elderly and immunocompromised individu-
als, and to a significant immune memory in response to 
the boosters [9]. Three different types of PCV are cur-
rently available: the 7-valent (PCV7), the 10-valent 
(PCV10) and the 13-valent (PCV13). All the PCVs are 
demonstrated to be effective against both invasive (i.e. 
Invasive Pneumococcal Diseases, IPDs, such as men-
ingitis, sepsis and bacteriemic pneumonia) and non-in-
vasive (e.g. AOM) pneumococcal diseases, but Italian 
Vaccination Plan suggests their usage only in children 
under the age of 5 [10]. As the Advisory Committee on 
Immunization Practices del Center for Disease Control 
and Prevention (CDC) does from 1997, Italian Minis-
try of Health recommends a booster of pneumococcal 
vaccination every 5 years with the 23-valent vaccine 
(PPV23) in elderly and adult high risk groups (e.g. im-
munocompromised individuals) with the particular pur-
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Summary
Introduction. Incidence of invasive pneumococcal diseases 
(IPDs) in Italy is constantly increasing and that is particularly true 
among the elderly. 23-valent polysaccharide pneumococcal vac-
cine (PPV23) is recommended to this age group and offered in all 
Italian regions. However, efficacy of PPV23 on preventing IPDs is 
debated. We therefore performed a review of the most recent avail-
able meta-analyses in order to assess the efficacy of PPVs. 
Methods. The literature search was conducted using PubMed and 
Scopus search engines. We used the following keywords: “pneu-
mococcal”, “polysaccharide”, “vaccine”, “efficacy”, “elderly”, 
“meta analysis”. Only meta-analyses published in the last 7 years 
were selected. We examined the results of the selected meta-anal-
yses and assessed their quality according to the PRISMA recom-
mendations. 
Results. The search returned 16 results in PubMed and 12 in 
Scopus: among them we selected 3 meta-analyses. According to 
our quality assessment, all meta-analyses showed generally posi-
tive results and almost all items of the PRISMA checklist were 
respected. However, the research protocol and the registration 
number were absent in all the 3 revisions and the flow-chart was 
not shown in Moberley’s and Melegaro’s works.
In the study by Huss et al. the relative risk of developing IPDs 
among vaccinated subjects was 0.90 (95%CI: 0.46-1.77, I² 4.9%), 
indicating a very slight benefit after vaccination. This contrasts with 
the results of the Cochrane Review by Moberley et al., in which the 
PPVs showed a protective efficacy in reducing the risk of IPDs of 
74% (OR 0.26, 95%CI: 0.15-0.46) with no statistical heterogeneity 
(I² 0%). Melegaro et al. found a reduction not statistically signifi-
cant of the incidence of IPD of 65% (OR 0.35; 95%CI 0.08-1.49) 
among healthy elderly, while the global estimate of vaccine efficacy 
among high risk elderly was minimal (OR 0.80; 95%CI 0.22-2.88). 
Conclusions. Most of the studies suggest that the PPVs confer 
low protection against IPDs. Anyhow, their methodological het-
erogeneity does not allow definitive conclusions. 
While waiting to see the results of new trials about the efficacy 
of PPVs, in particular of PPV23, and the extension of the use of 
conjugate vaccine among the population over 65, stakeholders 
should be aware of the results of the meta-analyses discussed in 
this paper during the implementation of the vaccination programs 
for the elderly in Public Health. 
The full article is free available on www.jpmh.org
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pose of preventing IPDs [10]. These diseases are in fact 
the cause of the highest rates of pneumococcal mortality 
among the elderly, with a rising trend observed over the 
last 20 years and intended to follow for the next years. 
The efficacy of PPV23 in preventing IPDs in the elderly has 
been analyzed in many primary and secondary studies, with 
opposed results. For this reason we performed a review of 
the most recent meta-analyses available on this topic.
Methods
We conducted a literature search using PubMed and 
Scopus search engines using the following keywords: 
“pneumococcal”, “polysaccharide”, “vaccine”, “effica-
cy”, “elderly”, “meta analysis”. The search was updated 
until 30th September 2011 but only meta-analyses pub-
lished in the last 7 years were selected. 
The following step was the reading of selected studies 
and the analysis of results with respect to the IPDs. Fi-
nally, two assessors independently evaluated the qual-
ity of papers according to the PRISMA recommenda-
tions [11], with the consultation of a third researcher for 
solving disagreements. 
Results
The search returned 16 results in PubMed and 12 in Sco-
pus. Among them, the 3 following meta-analyses were 
selected: Huss et al. 2009, Moberley et al. 2008, Mel-
egaro et al. 2004 (Fig. 1) [12-14]. 
According to our quality assessment, all meta-analyses 
showed positive results, and almost all items of the 
PRISMA checklist were respected. However, the re-
search protocol and the registration number were absent 
in all the 3 revisions, and the flow-chart was not shown 
in Moberley’s and Melegaro’s works.
In all the 3 studies the efficacy of the different types of 
PPV was assessed, even if the most used and suggested 
for the adult in Italy, as well as in the rest of European 
and American countries, is PPV23. 
In the study by Huss et al., 22 trials were included, 8 
of which examined the efficacy of PPV23: three were 
focused on high risk subjects with chronic comorbidities 
(chronic obstructive pulmonary diseases, HIV), 3 on sol-
diers and 2 on adults and elderly. Among these trials, on-
ly the one by Alfageme et al. (2006) and the Swedish one 
from Örtqvist et al. (1998) were included in the Cochrane 
Review; the Swedish trial abovementioned, together 
with the study by Honkanen et al. (1999), were those 
about PPV23 analyzed in the Melegaro’s review [13]. 
All the other trials included in the Cochrane and in the 
Melegaro et al. reviews were focused on polysaccharide 
antipneumococcal vaccines against less serogroups (i.e. 
PPV3, PPV12, PPV13, PPV14, and PPV17). 
Fifteen Randomized Controlled Trials (RCT) were se-
lected in the Cochrane Review, with a total number of 
48,656 subjects recruited. Melegaro et al. analyzed 6 
RCT and 3 quasi-randomized trials, 5 of which were 
conducted in European countries. 
In the study by Huss et al. the relative risk of developing 
IPDs among vaccinated subjects was 0.90 (95%CI 0.46-
1.77, I² 4.9%), indicating a small benefit after vaccination. 
This contrasts with the results of the Cochrane Review by 
Moberley et al., in which the PPVs showed a protective effi-
cacy in reducing the risk of IPDs of 74% (OR 0.26, 95%CI 
0.15-0.46), with no statistical heterogeneity (I² 0%). Six of 
the 8 trials included in the Melegaro et al. review assessed 
the efficacy of PPVs against IPDs only: two of them target-
ed the elderly and showed a reduction not statistically sig-
nificant of the incidence of IPD of 65% (OR 0.35; 95%CI 
0.08-1.49). In the other studies, focused on high risk elderly, 
the global estimate of vaccine efficacy against IPDs was 
minimal and not statistically significant (OR 0.80; 95%CI 
0.22-2.88). The previous meta-analysis included in Mel-
egaro et al. found a similar level of protection both among 
elderly, with a vaccine efficacy between 66% (52-76%) and 
82% (66-91%), and among high risk elderly, with results of 
low efficacy not statistically significant. 
Fig. 1. Flow-chart of selection process.
COPD: chronic obstructive pulmonary disease.
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Discussion
The difference in efficacy estimates of PPVs has been 
widely debated, especially by Huss et al. and in the Co-
chrane Review, and not only in their two systematic re-
views but also in following commentaries between these 
Authors. 
The most important and evident difference regards the 
results about the efficacy of PPVs in preventing IPDs: 
this contrast is probably due to the exclusion by Huss 
et al. of 2 trials included in the Cochrane Review but 
considered by the first Authors inadequate in terms of 
quality of diagnostic procedures and randomization of 
patients, respectively [12]. 
In fact, the main problem in evaluating efficacy of PPVs 
in preventing IPDs, as well as pneumonia, stays actu-
ally in the comparison of results coming from available 
trials. As already stated by Huss et al., high heterogene-
ity can be found not only in the populations recruited in 
each trial (elderly, risk groups affected by different co-
morbidities, particular categories such as soldiers), but 
also in the blinding (open, controlled, double-blind), in 
the duration of follow-up (which sometimes is not even 
reported), and in the concealment of the allocation, of-
ten judged as unclear. Moreover, as already discussed by 
other Authors, there are no sufficient data useful to pro-
vide a systematic review and meta-analysis that could 
report robust results about the efficacy of PPV23, the 
vaccine most currently used in Western countries for the 
prevention of pneumococcal diseases in children older 
than 5 and in adults. 
Conclusions
The heterogeneity of trials conducted until today on PPVs, 
which is reflected in different results, and the absence of a 
statistical significance in their findings do not allow defin-
itive conclusions about the efficacy of PPVs in preventing 
pneumococcal diseases and their consequences. 
Anyway, some studies suggest that PPVs confers very 
low protection against IPDs, in line with the conclu-
sions of other observational studies about this top-
ic [15, 16]. 
While waiting to see the results of the extension of the 
use of conjugate vaccine, especially the new 13-valent, 
among the population over 65, stakeholders should be 
aware of the results of meta-analyses discussed in this 
paper during the implementation of vaccination pro-
grammes for the elderly in Public Health. 
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